tirzepatide cvot trial Cardiovascular outcomes of semaglutide and for patients with type 2 diabetes in clinical practice Tirzepatide: A Systematic Update

In one trial of nearly 2,000 adults with obesity, but not type 2 diabetes, those taking 2.4 mg of semaglutide (a typical maintenance dosage for Wegovy) lost nearly 15% of their body weight in about a year and a half

7.3 Dermatological Reactions Mild rash Itching Skin reactions are usually mild but should be monitored for progression

Lilly could cut its price hard and still make money, in a way Novo just cant match on a peptide

Many patients find abdominal injections easier to perform since you can see the injection site clearly

Some users hit the copper uglies phase here, where skin briefly looks worse before it gets better

It works by mimicking hormones that regulate blood sugar and appetite, helping patients lose weight faster and more efficiently